Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
BörsenkürzelALBT
Name des UnternehmensAvalon Globocare Corp
IPO-datumFeb 22, 2016
CEOJin (David)
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 22
Addresse4400 Route 9
StadtFREEHOLD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl07728
Telefon17327804400
Websitehttps://www.avalon-globocare.com/
BörsenkürzelALBT
IPO-datumFeb 22, 2016
CEOJin (David)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten